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Abstract
Background: Insulin degrading enzyme (IDE) is a major protease of amyloid beta peptide (Aβ), a prominent toxic
protein in Alzheimer’s disease (AD) pathogenesis. Previous studies suggested that statins promote IDE secretion;
however, the underlying mechanism is unknown, as IDE has no signal sequence.
Results: In this study, we found that simvastatin (0.2 μM for 12 h) induced the degradation of extracellular Aβ40,
which depended on IDE secretion from primary astrocytes. In addition, simvastatin increased IDE secretion from
astrocytes in a time- and dose-dependent manner. Moreover, simvastatin-mediated IDE secretion was mediated by
an autophagy-based unconventional secretory pathway, and autophagic flux regulated simvastatin-mediated IDE
secretion. Finally, simvastatin activated autophagy via the LKB1-AMPK-mTOR signaling pathway in astrocytes.
Conclusions: These results demonstrate a novel pathway for statin-mediated IDE secretion from astrocytes.
Modulation of this pathway could provide a potential therapeutic target for treatment of Aβ pathology by
enhancing extracellular clearance of Aβ.
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Background
Alzheimer’s disease (AD) is the most common form of
dementia; it is characterized by senile plaques, neurofibril-
lary tangles, and neuronal cell death [1, 2]. Abnormally in-
creased levels of amyloid beta peptides (Aβ) lead to
formation of extracellular senile plaques and are associ-
ated with neurodegeneration in AD [3, 4]. The Aβ levels
in the brain are not only determined by the rate of
production by amyloid precursor protein (APP) process-
ing [5, 6], but also by several clearance mechanisms. These
include proteolytic degradation of extracellular Aβ by cell
surface-localized and/or secreted proteases such as nepri-
lysin (NEP), matrix metalloproteinase-9 (MMP-9), and
insulin-degrading enzyme (IDE) [7–9]. NEP is located
mainly in the plasma membrane, and its catalytic domain
faces the extracellular space [7]. MMP-9 and IDE can be
secreted extracellularly and degrade extracellular Aβ, des-
pite the fact that IDE has no signal sequence for secretion
through a conventional secretory pathway [10]. Many
studies have demonstrated that IDE is secreted [11]; how-
ever, the mechanism of secretion is still elusive.
Macroautophagy (hereafter referred to as autophagy)
is a fundamental biological process in eukaryotes and
has an impact on essential biological processes including
aging, cancer, neurodegenerative diseases, and metabolic
disorders [12, 13]. Autophagy is currently best known as
a degradative pathway that delivers cytoplasmic mate-
rials and organelles to the lysosomes for degradation
[14]. All autophagy-related processes include the formation
of double-membrane structures called autophagosomes
and are induced by the inhibition of the mammalian target
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of rapamycin (mTOR) signaling pathway. Autophagosomes
and their contents undergo clearance upon fusion with an
endosome (amphisomes) or lysosome (autolysosomes) for
degradation and recycling (autophagic flux) [12, 13, 15].
However, recent studies show that autophagy also has a
role in non-autophagic processes, especially in the secretory
pathway [16]. In eukaryotic cells, the autophagy-based
secretory pathway regulates the unconventional secretion
of several cytosolic proteins or factors such as IL (interleu-
kin)-1β, IL-18, High-mobility Group Box 1 (HMGB1), ATP
(adenosine triphosphate), Aβ, and von Willebrand factor
[17–20]. These proteins share important features, including
the lack of a signal sequence for conventional secretion,
and the contribution of autophagy-related (Atg) protein to
their secretion.
Several studies report that increased cholesterol levels
might be related to AD [21, 22], and that statin-mediated
inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase decreases cholesterol levels; thus,
reducing Aβ levels [23, 24]. However, this is controversial
[22]. Several studies have demonstrated that statins can
decrease the generation of Aβ by enhancing non-
amyloidogenic processing of APP [25, 26]. In addition, sta-
tins also impair the generation of isoprenoids, which play
important roles in the post-translational modification of
proteins in the Rho and Rab families [26, 27]. Isoprenoids
regulate the localization and biological function of Rho
and Rab proteins, and affect Aβ generation by modulating
APP processing [27]. Previous studies have also shown
that statins promote Aβ degradation by microglia via IDE
secretion [24]. However, the molecular mechanisms by
which statins could offer protection against AD have not
been studied extensively.
In this study, we found that IDE secretion from pri-
mary astrocytes was increased by statins in a time- and
concentration-dependent manner, and statin-induced
IDE secretion was associated with autophagy-based un-
conventional secretion. Additionally, we found that au-
tophagic flux is important in IDE secretion and that
statin activates autophagy in astrocytes via the LKB1-
AMPK-mTOR signal pathway. These results indicate
that IDE is secreted from astrocytes via an autophagy-
based secretory pathway, and that regulation of autoph-
agy is a potential therapeutic target in Aβ pathology.
Results
Statins induce extracellular secretion of functional IDE
from astrocytes
Previous studies have shown that astrocytes are the main
source for IDE in AD pathology [28]. Therefore, we first
determined whether statins regulate IDE levels in the
extracellular space of astrocytes. We found that simva-
statin increased IDE secretion from primary astrocytes
in a time- and dose-dependent manner (Fig. 1a-c), and
that IDE levels in the cells were reduced conversely
(Fig. 1a, b). Because statins are known to lower choles-
terol levels, we checked whether statins regulate choles-
terol levels in astrocytes. By using a filipin assay, we
found that simvastatin reduced intracellular cholesterol
levels (Additional file 1: Figure S1A,B). To determine
whether only simvastatin induced IDE secretion from as-
trocytes, one of the other known statins, fluvastatin, was
applied to astrocytes; we found that fluvastatin also in-
creased IDE secretion (Additional file 2: Figure S2A,B).
To examine whether the IDE secreted by statin treat-
ment functions as insulysin (having an insulin-degrading
function), we utilized an IDE enzymatic activity assay.
We detected an increased in fluorescent intensity gener-
ated by the cleavage of fluorometric IDE substrates in
the statin-treated astrocyte-conditioned media (ACM)
(Fig. 1d). In an alternative approach, we performed an
Aβ degradation assay. When the statin-treated ACM
was incubated with the recombinant Aβ40 peptide, the
level of the remaining Aβ40 peptide was reduced (Fig. 1e;
lane 1 vs. lane 2). Furthermore, the reduced Aβ40 levels
after incubation with the statin-treated ACM were
restored when bacitracin A, an IDE inhibitor, was added
(Fig. 1e; lane 2 vs. lane 6). The inhibitors of other known
Aβ degrading enzymes including thiorphan, a NEP
inhibitor, or GM6001, a MMP inhibitor, did not restore
the reduced Aβ40 levels by the statin. These data demon-
strate that statins induce IDE secretion from astrocytes,
and statin-induced IDE functions as a protease to de-
grade the Aβ peptide.
Statin-mediated IDE secretion from astrocytes is
associated with an autophagy-based unconventional
secretory pathway
To examine the mechanism of statin-induced IDE secre-
tion, transcript levels of IDE after statin treatment were
measured by quantitative real-time PCR (qPCR). Simva-
statin did not alter ide mRNA levels in astrocytes
(Fig. 2a). Because IDE has no signal sequence for secre-
tion, we further investigated the secretory mechanism of
IDE. Previous studies showed that statins could stimu-
late secretion of IDE proteins via an unconventional
pathway in association with exosomes [24]. To determine
whether statin-induced IDE secretion is associated with
exosomes in astrocytes, both exosomes and non-exosome
fractions were isolated from vehicle- or statin-treated
ACM. We found that simvastatin increased secreted IDE
levels both in the exosomes and non-exosome fractions
(Additional file 3: Figure S3), indicating that the secretory
pathway for IDE is mediated by both exosome- and non-
exosome-associated pathways. To determine the exact
mechanisms of IDE secretion by statin, we focused on the
autophagy-based unconventional secretory pathway. We
used immunostaining and western blot analysis and found
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that statin treatment activated autophagy (Fig. 2b,c). In
addition, we found that statin-induced IDE secretion was
blocked by autophagy inhibition (Fig. 2c–e). Treatment
with 3-methyladenine (3MA), a well-known autophagy
inhibitor (Fig. 2c,d), or the knock-down of Beclin1, a key
component of autophagy-initiation complex, reduced
statin-induced IDE secretion from astrocytes (Fig. 2e). In
the IDE enzymatic assay, 3MA inhibited increased IDE ac-
tivity by statin treatment (Fig. 2f). To visualize whether IDE
exists in the autophagosomes, IDE and LC3 were stained
with their specific antibodies, followed by observation using
confocal microscopy. Immunocytochemistry data showed
that IDE was located in the autophagosomes, and simva-
statin increased the level of IDE in the autophagosomes
(Fig. 2g,h). Taken together, these data imply that statin-
induced IDE secretion is tightly regulated by the autophagy
pathway in astrocytes.
Statin-mediated IDE secretion from astrocytes is
regulated by autophagic flux
Previous studies showed that secretion of IL-1β, one of the
substrates for autophagy-based unconventional secretion,
Fig. 1 Statin treatment induces extracellular secretion of functional insulin-degrading enzyme (IDE) from astrocytes. a & b Increased IDE levels
secreted from the primary astrocytes by simvastatin in a concentration-(a) and time-(b) dependent manner. The time points mean the time
period of simvastatin treatment. Blots are representative of at least three independent experiments (N = 3 experiments). ** p < 0.01, # p < 0.05, ##
p < 0.01 vs. vehicle-treated cells. c Secreted IDE levels by simvastatin with IDE ELISA. d IDE enzymatic activity in the media from simvastatin-treated cells.
(e & f) Cell-free Aβ degradation assay. The arrowhead indicates remaining Aβ40 levels. Data were obtained from at least three replicates for each group
(N = 3 experiments). rIDE, recombinant IDE protein; Thio, thiorphan; Baci. A, Bacitracin A. ** p < 0.01, *** p < 0.001 vs. vehicle-treated cells; ## p < 0.01 vs.
cells treated with simvastatin
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was inhibited by lysosomal dysfunction that was induced by
treatment with bafilomycin [17]. To further examine the
statin-induced IDE secretory pathway, we determined if
autophagic flux was blocked by bafilomycin, a lysosomotro-
pic agent that prevents lysosomal acidification and autop-
hagosomal cargo degradation. Using the LysoTracker
probe, we found that bafilomycin inhibited lysosomal activ-
ity (Fig. 3a). In addition, treatment with bafilomycin
decreased IDE secretion from astrocytes and led to accu-
mulation of IDE proteins in the cells (Fig. 3b,c), suggesting
that autophagic flux is important for IDE secretion.
Statin activates autophagy via the AMPK-mTOR signaling
pathway in astrocytes
To investigate the mechanism of autophagy activation
by statins, astrocytes were treated with an inhibitor of
AMP-activated protein kinase (AMPK). Previous studies
have shown that statin treatment induces AMPK activa-
tion [29] and the AMPK-mTOR signaling pathway regu-
lates autophagy initiation [30]. When compound C, a
well-known AMPK-specific inhibitor [31], was applied
with simvastatin to astrocytes, it blocked the statin-
induced phosphorylation of AMPK (Fig. 4a,b). We also
Fig. 2 Statin −mediated IDE secretion from astrocytes is associated with an autophagy-based unconventional secretory pathway. a Quantification
of ide mRNA levels by qPCR. b Autophagy activation in astrocytes by simvastatin. Anti-LC3 antibody was used to detect autophagy. Scale bar
represents 5 μm. c Western blot analysis of secreted IDE levels from astrocytes after treatment with the autophagy inhibitor in the presence of
simvastatin. d Quantitative analysis of Fig. 2c. Data were obtained from at least three replicates for each group (N = 3 experiments). e Western
blot analysis of IDE levels in the media from Beclin1 knock-down astrocytes. f IDE enzymatic activity in the media from simvastatin and/
or 3MA-treated cells. g Confocal microscopy images of IDE expression in the autophagosomes. Scale bar represents 8 and 6 μm (enlarged
images). h Quantitative analysis of IDE in association with the autophagosome marker (LC3) with the Image J program (NIH, MD, USA).
Data were obtained from at least three replicates (N = 3 experiments). ** p < 0.01 vs. vehicle-treated cells; # p < 0.05 vs. cells treated with
simvastatin. n.s. indicates no significant difference
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observed that statin treatment decreased the phosphor-
ylation of mTOR, and increased LC3-II levels (Fig. 4a,
b). Conversely, compound C reversed these changes in
mTOR kinase and LC3-II levels by statins (Fig. 4a, b). In
addition, compound C inhibited statin-induced IDE secre-
tion significantly (Fig. 4a, b). To visualize the alterations in
autophagosome formation caused by the AMPK-specific
inhibitor directly, immunocytochemistry was performed
after co-treatment with compound C and statin. Statin
treatment alone increased the punctate signal of LC3
(Fig. 4c), indicating enhanced autophagosome formation.
Compound C prevented this increase, suggesting that
AMPK signaling is required for statin treatment to
promote autophagosome formation in astrocytes.
Simvastatin does not regulate MMP-9 and NEP levels in
astrocytes
In above data, simvastatin activated autophagy via
AMPK-mTOR pathway, and statin-induced autophagy
activation is neccessary for IDE secretion. To investigate
whether other Aβ degradation enzymes such as MMP-9
and NEP can be also regulated by autophagy, MMP-9
and NEP levels were measured with media and cell ly-
sates under simvastatin and/or Compound C treated
condition. We found that simvastatin did not alter
MMP-9 and NEP levels (Fig. 4d and e).
LKB1, but not CaMKKβ, mediates the statin-mediated
phosphorylation of AMPK
In previous studies, 2 upstream kinases were reported to
activate AMPK, liver kinase B1 (LKB1) and Ca2+/cal-
modulin-dependent protein kinase kinase-beta (CaMKKβ)
[32, 33]. We found that statin treatment induced LKB1
phosphorylation (Fig. 5a), and LKB1-specific siRNA failed
to induce statin-induced phosphorylation of AMPK or
generation of LC3-II (Fig. 5b-d), indicating that LKB1 is
an AMPK upstream kinase for statin-induced autophago-
some formation in astrocytes. When CaMKKβ-specific
Fig. 3 Statin-mediated IDE secretion from astrocytes is regulated by autophagic flux. a Lysosomal activity as determined with LysoTracker probe.
Scale bar represents 10 μm. b Change in secreted IDE levels by inhibiting lysosome with bafilomycin. c & d Quantitative analysis of Fig. 3b (N = 3
experiments). Baf, bafilomycin. ** p < 0.01, # p < 0.05 vs. vehicle-treated cells
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siRNA was transfected into astrocytes, statin-induced
phosphorylation of AMPK and levels of LC3-II were not
altered (Fig. 5b-d), indicating that CaMKKβ is not re-
quired for statin-induced autophagosome formation in as-
trocytes. These data imply that LKB1, not CaMKKβ,
mediates statin-induced AMPK phosphorylation and then
induces autophagosome formation.
Discussion
In this study, we first demonstrated that statin treatment
could induce extracellular IDE secretion from astrocytes
via an autophagy-based unconventional secretory pathway
(Fig. 6). Secreted IDE can significantly degrade extracellular
Aβ peptides, indicating that it may be important for AD
progression. In microglia, IDE, which has no known signal
sequences, is secreted under statin-treated conditions via
an exosome associated unconventional secretory pathway
[24]. To determine whether statin-induced IDE secretion
is associated with exosomes in astrocytes, both exosomes
and non-exosome fractions were isolated from vehicle- or
statin-treated astrocyte-conditioned media (ACM). We
found that statin application increased IDE secretion from
both the exosome and non-exosome fractions (Additional
file 3: Figure S3), indicating that the secretory pathway for
IDE is mediated by both exosome- and non-exosome-
associated pathways. We also found that statin treatment
Fig. 4 Statin activates autophagy via AMPK-mTOR signaling pathway in astrocytes. a Inhibition of statin-mediated autophagy activation and
IDE secretion by treatment with AMPK inhibitor (Compound C; CC). b Quantitative analysis of Fig. 4a (N = 3 experiments). * p < 0.05, ** p < 0.01
vs. vehicle-treated cells; # p < 0.05, ## p < 0.01 vs. cells treated with simvastatin. c Inhibition of statin-mediated autophagy activation by treatment
with compound C. Anti-LC3 antibody was used to detect autophagy. Scale bar represents 6 μm. Lower panels show figures under higher
magnification. Scale bar represents 2 μm. d The effect of statins on regulation of MMP-9 and NEP levels. e Quantitative analysis of Fig. 4d
(N = 3 experiments)
Son et al. Molecular Neurodegeneration  (2015) 10:56 Page 6 of 11
increased functional IDE secretion in a time- and dose-
dependent manner, and statin-induced IDE secretion was
blocked by autophagy inhibition although IDE secretion at
basal condition might be mediated by an autophagy-
independent pathway (Fig. 2d-f). Because the fundamental
role of autophagy is the clearance of protein aggregates
and pathogens [13], we determined whether statin-
mediated IDE secretion is regulated by the autophagy-
lysosome pathway. When lysosomes were disrupted by
the lysosomal inhibitor bafilomycin, IDE secretion was
blocked, indicating that autophagic flux is important for
statin-mediated IDE secretion. In this study, cell death
was not observed under several drug-treated conditions
(Additional file 4: Figure S4).
Astrocytes have an important role in maintaining
neuronal homeostasis by providing energy and eliminat-
ing waste [34]. In addition, astrocytes are well positioned
both metabolically and anatomically to play an import-
ant homeostatic role under basal conditions as well as
pathological conditions. Previous studies have shown
that at an early stage of AD, activated astrocytes sur-
round and infiltrate Aβ plaque [35, 36]. Although their
exact role in AD pathogenesis remains unknown, react-
ive astrocytes have been shown to play a role in the
clearance of Aβ suggesting a neuroprotective role in AD
[37]. For the removal of extracellular Aβ, astrocytes take
up Aβ bound to membrane receptors, such as LRP1, via
endocytosis and degrade Aβ [38]. In addition, astrocytes
are capable of degrading Aβ enzymatically by secretion
of MMP-9 and IDE extracellularly [39, 40]. Especially, in
AD pathology, astrocytes are the main source for IDE
[28]. Our results provide evidence that in statin-treated
conditions, astrocytes can release IDE extracellularly via
an autophagy-based secretory pathway, and the secreted
IDE could then degrade extracellular Aβ. To determine
whether secretion of other Aβ degrading enzymes such
as NEP or MMP-9 is induced by autophagy similarly to
IDE, we found that simvastatin did not induce secretion
of NEP and MMP-9 (Fig. 4d and e). Previous studies
have indicated that NEP is located mainly in the plasma
membrane [7], and secretion of MMP-9 is mediated
through a conventional secretory pathway, as MMP-9
has signal peptides for secretion [9]. Therefore, among
Aβ-degrading enzymes, only IDE may be secreted by an
autophagy-based secretory pathway.
There are many reports that elevated levels of choles-
terol increase the risk for AD and that statins can regu-
late AD progression [21, 22]. Several studies have
Fig. 5 Statin-induced AMPK activation is mediated by LKB1 in astrocytes. a Increased phosphorylation of LKB1 by treatment with simvastatin. b
Statin-induced autophagy activation and IDE secretion levels in CaMKKβ or LKB1 knock-downed cells. c & d Quantitative analysis of Fig. 5b (N = 3
experiments). * p < 0.05, ** p < 0.01 vs. vehicle-treated cells. n.s. indicates no significant difference
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reported beneficial effects of statin treatment on AD
pathology [24, 41]. However, some studies did not report
any positive effects of statin; statin treatment actually in-
creased Aβ levels [22, 42]. Such variable conclusions
might stem from the fact that most of these studies were
conducted with randomized concentrations of statins
and time of statin treatment (early stage or late stage of
AD) and the differential ability of statins to cross the
blood-brain barrier (BBB) [24]. In our data, lysosomal
dysfunction by treatment with bafilomycin inhibited
statin-mediated IDE secretion. Because late-stage AD
brains show autophagy accumulation and lysosomal
dysfunction [43], it is possible that statins may not be
beneficial when administered to patients with late-
stage AD.
Abnormally pathological autophagic vacuoles (AVs)
accumulate in the brains of patients with AD and in
brains from animal models of AD [44]. The excessive
autophagosome formation might result from increased
induction via the AMPK-mTOR pathway and dysfunc-
tion in autophagy-lysosomal degradation [31, 43]. Be-
cause maintaining autophagic flux is important for cell
survival [13], dysregulated autophagy could accelerate
AD progression; however, the mechanism is not yet fully
understood. In this study, impaired autophagic flux
inhibited statin-mediated IDE secretion from astrocytes;
the reduced IDE secretion from astrocytes could lead to
an increase in extracellular Aβ levels. The regulation of
Aβ levels is of great interest for AD treatment. Apart
from the interference with Aβ generation, a promising
alternative may be the enhancement of Aβ degradation
by targeting Aβ-degrading enzymes [45]. Thus, regulat-
ing IDE secretion by statins in astrocytes may lead to
new therapeutic approaches for sporadic AD.
Conclusions
Our data collectively suggest that statin treatment can
induce extracellular IDE secretion from astrocytes via an
autophagy-based unconventional secretory pathway.
Because secreted IDE can significantly decrease in extra-
cellular Aβ levels, modulation of this pathway could pro-
vide a potential therapeutic target for treatment of Aβ
pathology.
Methods
Cell cultures, drug treatments, and transfection
Primary astrocytes were prepared from newborn (P1)
ICR mice as described previously [46]. The cells under-
went two passages for the experiments and were grown
in DMEM supplemented with 10 % fetal bovine serum
(FBS; HyClone, Irvine, CA, USA) and 0.1 mg/ml P/S
(Penicillin-Streptomycin; Sigma-Aldrich, St. Louis, MO,
USA) at 37 °C in humidified 5 % CO2 incubator for
2 weeks. The cells were treated with several reagents
alone, or co-treated with simvastatin followed by 24 h
incubation. Reagents used in this study were thiorphan
Fig. 6 Schematic diagram. Statins activate autophagy via the LKB1-AMPK-mTOR signaling pathway in astrocytes, and statin-mediated IDE secretion is
mediated by an autophagy-based unconventional secretory pathway. Finally, secreted IDE can significantly decrease in extracellular Aβ levels, thus,
modulation of this pathway can regulate AD progression by enhancing Aβ clearance
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(T6031; NEP inhibitor), bacitracin A (B0125; IDE inhibi-
tor), 3MA (M9281; autophagy blocker), bafilomycin
(B1793; selective inhibitor of vacuolar-type H+-ATPase),
simvastatin (S6196), fluvastatin (SML0038), STO-609
(S1318; CaMKKβ inhibitor), methyl-β-cyclodextrin
(MβCD) (C4555; cholesterol‐lowering compound) from
Sigma-Aldrich; compound C (171260; AMPK inhibitor)
from Calbiochem (San Diego, CA, USA); GM6001
(142880-36-2; MMP inhibitor) from Tocris Bioscience
(Bristol, UK). The siRNAs were purchased from Bioneer
Inc. (Daejeon, Korea) (1330628 for beclin 1, 1432200 for
lkb1, 1334167 for camkk2), and were transfected into the
cells using RNAimax (13778) (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions.
Western blot analysis
Harvested cell pellets and media were prepared as de-
scribed previously [47]. Briefly, cell pellets were lysed in
RIPA buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1 %
NP-40, 0.5 % NaDoc, 0.1 % SDS) containing protease in-
hibitors (Sigma-Aldrich). After sonication at 4 °C, 10 μg of
lysate was separated on SDS-PAGE gels and then trans-
ferred to PVDF membranes. Membranes were incubated
with antibodies against the indicated proteins in this
study. The antibodies for the western blot analysis were:
anti-LC3B antibody (1:2,000; M152-3, MBL, Woburn,
MA, USA; 2775, Cell Signaling Technology, Beverly, MA,
USA); 6E10 (1:5000; SIG-39300, Covance, Princeton, NJ,
USA); anti-p-LKB1 (S428), anti-AMPK (2532), anti-p-
AMPK (T172) (2535) and anti-p-mTOR (S2448)
(5536) (1:2000, Cell Signaling Technology); anti-LKB1
(sc-32245), anti-IDE (N-15) (sc-27265) and anti-mTOR
(sc-1549) (1:1,000; Santa Cruz Biotechnologies Inc., Santa
Cruz, CA, USA); anti-IDE (ab32216), anti-GAPDH
(ab9485), anti-TSG101 (ab83) and anti-beclin1 (ab62472)
(1:2,000; Abcam, Cambridge, MA, USA); anti-p62
(P0067), and anti-β-actin (A1978) (1:4,000; Sigma-
Aldrich). Immunoreactivity was determined by chemilu-
minescence (GE Healthcare, Piscataway, NJ, USA). The
chemiluminescence signal was detected with a digital
image analyzer (LAS-3000; Fuji, Tokyo, Japan).
Aβ degradation assay
The Aβ degradation assay was performed as previously
described with modification [24]. Briefly, primary astro-
cytes grown in a 6-well plate were incubated with simva-
statin or DMSO (vehicle) in serum-free DMEM for 24 h.
The supernatant was then collected after centrifugation
and incubated with 1 μM recombinant human Aβ40
(American Peptide, Sunnyvale, CA, USA) for 12 h at
37 °C in the absence or presence of 5 μM GM6001,
5 μM thiorphan, 20 μM bacitracin A or 0.3 μg/μl recom-
binant IDE (rIDE). Remaining Aβ40 levels were quanti-
fied with 6E10 antibody by western blot analysis.
Trichloroacetic acid (TCA) precipitation
For analyzing protein in the medium, we performed
TCA precipitation as previously described [48]. Briefly,
cell medium was centrifuged at 2,400 g for 5 min to re-
move cell debris and then subjected to TCA precipita-
tion (up to 10 %) (T6399, Sigma-Aldrich).
IDE activity assay and IDE level measurement in the
media
The IDE enzymatic activity in media was determined per
manufacturer's protocol (CBA079, Calbiochem). Briefly,
50 μl of the concentrated media were loaded into in a
96-well plate, which contained an affinity-purified poly-
clonal antibody that recognizes IDE. The media were
concentrated with an Amicon Ultra filter (UFC510024,
Millipore, Billerica, MA). Following 1 h incubation,
fluorometric IDE substrates were added and incubated
for 2–4 h at 37 °C in the dark. The fluorescence was
measured using an excitation wavelength of 320 nm and
an emission wavelength of 405 nm. To determine the
level of IDE in media, ELISA was performed per manu-
facturer’s protocol (MBS725082, Mybiosource, San
Diego, CA, USA).
Measurement of lysosomal activity
The measurement of lysosomal activity with LysoTracker-
Red (L7528; Invitrogen) was performed as per manufac-
turer's protocol. The fluorescence intensity was observed
using a confocal laser scanning microscope (FV10i-w,
Olympus, Tokyo, Japan) and representative cells were se-
lected and photographed.
Quantitative real-time PCR (qRT-PCR)
To examine the levels of IDE mRNA, qRT-PCR was per-
formed as previously described [49]. RNA was isolated
using the RNeasyPlus Mini Kit (Qiagen, Valencia, CA,
USA) and cDNA was generated using the RevertAid
First Strand cDNA Synthesis Kit (Fermentas, Glen Bur-
nie, MD). Real-time PCR was performed on the cDNA
samples using ABI StepOne 2.1 (Applied Biosystems,
Foster City, CA), and the following sense and antisense
primers were used: 5′-CCGGCCATCCAGAG AATAG
AA-3′ (sense), 5′- ACGGTATTCCCGTTTGTCTTCA-
3′ (antisense) for IDE.
Isolation and characterization of exosomes
Exosomes and non-exosome fractions in the media from
astrocytes were prepared as described earlier [50, 51]. In
brief, primary astrocytes from T175 flasks (four flasks
per one group) were cultured in DMEM with 10 % FBS.
One day before the exosome preparation, culture
medium was replaced to AIM-V medium w/ or without
simvastatin. Culture supernatants of cells grown for 24 h
in AIM-V medium were collected and spun at 300 g for
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10 min to remove cells. The supernatants were then se-
quentially centrifuged at 1,200 g for 20 min, 10,000 g for
30 min, and 100,000 g for 1 h. The 100,000 g pellet was
washed, and then again spun at 100,000 g for 1 h. The
second 100,000 g pellet (exosomal pellet) was resus-
pended in PBS, and the supernatants were used as non-
exosome fractions.
Immunostaining
Immunocytochemical staining was performed as described
previously [48, 52]. Briefly, the fixed cells were incubated
with mouse anti-IDE (1:300) and/or anti-LC3B (1:300) pri-
mary antibodies in PBST (PBS with 0.2 % Triton X-100)
buffer overnight at 4 °C. After several washes, the cells were
incubated with secondary antibody, and images were taken
using a confocal laser scanning microscope (FV10i-w;
Olympus).
Filipin staining
The filipin staining was determined as manufacturer's
protocol (F9765, Sigma-Aldrich). Briefly, the cells were
fixed with 4 % paraformaldehyde (PFA), and then were
incubated with 25 μg/ml filipin in PBS for 30 min at
room temperature. The images were taken using a con-
focal laser scanning microscope (FV10i-w; Olympus).
Cell viability assay
To measure cell viability, we used MTS assay kit
(#G3580, Promega, Madison, WI) according to the man-
ufacturer’s instructions. In Brief, the cells in a 96-well
microtiter plate were incubated in the absence or pres-
ence of various drugs. After 24 h incubation, we trans-
ferred an appropriate volume of MTS assay solution into
96-well plate and incubated the plate for 1 h at 37 °C in
the dark. The absorbance was measured using a plate
reader at 490 nm.
Statistical analysis
For western blots, protein levels were normalized to pan
forms or a housekeeping protein, such as β-actin or
GAPDH. All data were expressed as means ± standard
error of the mean (S.E.M.). Statistical analysis was per-
formed using GraphPad Prism 5 (San Diego, CA, USA).
The data were analyzed by one-way analysis of variance
with post-hoc test or unpaired t-tested regarded as ap-
propriate. P values of < 0.05 were considered statistically
significant.
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Additional file 1: Figure S1. Statins regulate cholesterol levels in
astrocytes. (A) Cellular cholesterol levels were measured by filipin
staining. MβCD is a positive control. (B) Quantitative analysis of Figure
S1A using the Image J program (N = 3 experiments). ** p < 0.01, ***
p < 0.001 vs. vehicle-treated cells. (PDF 217 kb)
Additional file 2: Figure S2. Fluvastatin induces IDE secretion from
astrocytes. (A) Increased IDE levels secreted from the primary astrocytes by
fluvastatin in a concentration-dependent manner. Blots are representative of
at least 3 independent experiments (N = 3 experiments). (B) Quantitative
analysis of Figure S2A. ** p < 0.01 vs. vehicle-treated cells. (PDF 71 kb)
Additional file 3: Figure S3. Statin-induced IDE secretion is mediated
by both exosome- and non-exosome-dependent pathways. (A) Western
blot analysis of IDE levels in the exosomes or non-exosome fractions.
TSG101 is an exosome marker protein. (PDF 30 kb)
Additional file 4: Figure S4. Cell death was not induced in this study.
(A) MTS assay was used for checking cell viability under simvastatin, 3MA
and/or bafilomycin treated condition. N = 5 experiments. (PDF 57 kb)
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